A5103209680- Lung Cancer Diagnosis and Treatment
- Radiation Therapy and Dosimetry
- Advanced Radiotherapy Techniques
- Lung Cancer Research Studies
- Head and Neck Cancer Studies
- Prostate Cancer Diagnosis and Treatment
- Prostate Cancer Treatment and Research
- Effects of Radiation Exposure
- Medical Imaging and Pathology Studies
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Atomic and Subatomic Physics Research
- Lung Cancer Treatments and Mutations
- Advanced Image Processing Techniques
- Radiation Detection and Scintillator Technologies
- Medical Imaging Techniques and Applications
- Congenital Diaphragmatic Hernia Studies
- Cardiac electrophysiology and arrhythmias
- Metastasis and carcinoma case studies
- Oral health in cancer treatment
- Cancer Mechanisms and Therapy
- Optical Coherence Tomography Applications
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Adolescent and Pediatric Healthcare
- Brain Metastases and Treatment
- Cardiac Imaging and Diagnostics
National Institutes for Quantum Science and Technology
2007-2025
Chiba Hospital
2020-2021
University of Tsukuba
2021
University of Rochester Medical Center
2018
Mitsubishi Electric (Japan)
2002
In 1994 a Phase I/II clinical study on carbon ion radiotherapy was begun at NIRS using HIMAC, which then the world's only heavy accelerator complex dedicated to medical use in hospital environment. Among several types of species, we have chosen ions for cancer therapy because they had most optimal properties terms possessing, both physically and biologically, effective dose-localization body. The purpose investigate efficacy against variety tumors as well develop techniques delivering an...
Although concurrent chemoradiotherapy (CCRT) has become the standard approach for unresectable locally advanced non-small cell lung cancer (LA-NSCLC), most patients are not candidates this treatment because of comorbidities. We evaluated safety and efficacy carbon ion radiotherapy (CIRT) in LA-NSCLC patients.Patients with stage IIA to IIIA (UICC 7th edition) were enrolled a sequential phase I/II trial. For I dose escalation study, total prescribed was increased by 4 Gray equivalents (GyE) 2...
Radiotherapy is a standard treatment for inoperable stage I non-small cell lung cancer (NSCLC), and carbon-ion radiation therapy (CIRT) may be used such treatment. Although CIRT NSCLC has demonstrated favorable outcomes in previous reports, the reports covered only single-institution studies. We conducted prospective nationwide registry study including all institutions Japan.Ninety-five patients with were treated by between May 2016 June 2018. The dose fractionations selected from several...
Abstract Anti-cancer treatments for lung cancer patients with interstitial disease (ILD) are challenging. The treatment options ILD often limited because of concerns that can cause acute exacerbation (AE) ILD. This study aimed to analyze the outcomes carbon-ion radiotherapy (CIRT) stage I non-small cell (NSCLC) ILD, using a multi-institutional registry. Patients who received CIRT NSCLC in institutions Japan were enrolled. indication was determined by an institutional multidisciplinary tumor...
Background: The aim of this study was to develop nomograms predicting 5- and 7-year biochemical-recurrence (BCR)-free survival in high-risk prostate cancer (PCa) patients treated with carbon-ion radiotherapy (CIRT) androgen deprivation therapy (ADT). Methods: We retrospectively evaluated 785 PCa CIRT ADT. Based on the least absolute shrinkage selection operator model, two BCR-free were developed internally validated. ability each nomogram predict determined by calculating area under curve...
Abstract There are no clinical reports of long‐term follow‐up after carbon‐ion radiotherapy (CIRT) using a dose 51.6 Gy (relative biological effectiveness [RBE]) in 12 fractions for localized prostate cancer, or comparison outcomes between passive and scanning beam irradiation. A total 256 patients with cancer who received CIRT at (RBE) two different delivery techniques (passive [ n = 45] 211]), were followed more than 1 year, analyzed. The biochemical relapse‐free (bRF) rate was defined by...
PurposeWe report herein the 3-year results of a phase I/II prospective study 4-fraction course carbon-ion radiotherapy (CIRT) in patients with localized prostate cancer.Materials and MethodsThe present was single-institution, including low- or intermediate-risk cancer, as defined by National Comprehensive Cancer Network criteria. Eligible were randomly assigned (1:1) to one- two-week schedule. Dose-limiting toxicities (DLTs) any genitourinary (GU) gastrointestinal (GI) toxicity grade 3...
<title>Abstract</title> <bold>Purpose:</bold> This study aimed to evaluate the prognostic predictive ability of MET-PET/CT-derived imaging biomarkers in patients with localized non-small cell lung cancer (NSCLC) undergoing single-fraction carbon-ion radiotherapy (CIRT) and clarify additional information these can provide beyond standard UICC staging protocol. <bold>Methods:</bold> With institutional review board approval, 67 NSCLC eligible for CIRT between 2007 2012 were included....
Lung cancer is frequently complicated by interstitial lung disease (ILD). Treatment protocols for patients with ILD have not been established; surgery, chemotherapy, and radiotherapy can all cause acute exacerbation of ILD. This study evaluated the toxicity efficacy carbon ion (CIRT) in non-small cell (NSCLC) ILD.Between June 2004 November 2014, 29 diagnosed NSCLC were treated CIRT. No patient was eligible curative surgery or conventional secondary to Owing prior symptomology, radiation...
The efficacy and safety of carbon‐ion radiotherapy ( CIRT ) for locally advanced non‐small‐cell lung cancer LA ‐ NSCLC remain unclear. We reported the clinical outcomes . Data 141 eligible patients who received between 1995 2015 were retrospectively analyzed. Local control LC ), locoregional LRC progression‐free survival PFS overall (OS calculated using Kaplan‐Meier method. median age was 75.0 years. Overall, 21 (14.9%), 57 (40.4%), 43 (30.5%) 20 (14.2%) had T1, T2, T3 T4 disease,...
Background: The purpose of the present study was to evaluate efficacy and safety single-fraction carbon-ion radiotherapy (CIRT) in patients with non-small cell lung cancer. Methods: Patients histologically confirmed cancer, stage T1-2N0M0, treated CIRT (50Gy (relative biological effectiveness)) between June 2011 April 2016 were identified our database retrospectively analyzed. Toxicity evaluated using Common Terminology Criteria for Adverse Events version 4.0. Results: included 57 patients,...
Introduction: The standard therapy for stage I non-small cell lung cancer (NSCLC) is surgery, but some operable patients refuse this option and instead undergo radiotherapy.Carbon-ion radiotherapy (CIRT) a type of radiotherapy.The Japanese prospective nationwide registry study on CIRT began in 2016.Here, we analyzed real-world clinical outcomes with NSCLC.Methods: All NSCLC treated Japan between 2016 2018 were enrolled.The dose fractionations selected from several options approved by the...
To moving lung tumors, we applied a respiratory-gated strategy to carbon-ion pencil beam scanning with multiple phase-controlled rescanning (PCR). In this simulation study, quantitatively evaluated dose distributions based on 4-dimensional CT (4DCT) treatment planning. Volumetric 4DCTs were acquired for 14 patients tumors. Gross tumor volume, clinical target volume (CTV) and organs at risk (OARs) delineated. Field-specific volumes (FTVs) calculated, 48Gy(RBE) in single fraction was...
We evaluated the efficacy and safety of carbon-ion radiotherapy (CIRT) alone for Stage III non-small-cell lung cancer (NSCLC).Data 65 patients (median age=73 years) with NSCLC who underwent CIRT in QST Hospital, Chiba, Japan, between 1997 2015 were retrospectively analysed. The median dose was 72.0 Gy (relative biological effectiveness).The follow-up 27.6 months (range=1.6-207.7 months). Two-year local control, progression-free survival (PFS), overall (OS) rates 73.9%, 38.6%, 54.9%,...
Intrathoracic recurrence after carbon‐ion radiotherapy for primary or metastatic lung tumors remains a major cause of cancer‐related deaths. However, treatment options are limited. Herein, we report on the toxicity and efficacy re‐irradiation with locoregionally recurrent, metastatic, secondary tumors. Data 95 patients prior intrathoracic who were treated at our institution between 2006 2016 retrospectively analyzed. Seventy‐three (76.8%) had 22 (23.2%) The median dose initial was 52.8 Gy...
Patients with lung cancer complicated by interstitial pneumonia (IP) often lose treatment options early owing to acute exacerbation of IP concerns. Carbon-ion radiotherapy (CIRT) can provide superior tumor control and low toxicity at high dose concentrations. We conducted a retrospective analysis the efficacy tolerability single-fraction CIRT using 50 Gy for IP-complicated cancer. The study included consecutive patients treated between April 2013 September 2022, whose clinical stage (UICC...
Carbon-ion radiotherapy (CIRT) is a promising treatment for locally advanced non-small-cell lung cancer, especially patients with inoperable cancer. Although the incidence of CIRT-induced radiation pneumonitis (RP) ≥ grade 2 ranges from 2.5 to 9.9%, association between RP and dosimetric parameters not clear. Herein, we identified prognostic factors associated symptomatic after CIRT Clinical results 65 treated 2000 2015 at National Institute Radiological Sciences were retrospectively...
Carbon ion radiotherapy (CIRT) has been expected to be an alternative for surgery early-stage non-small-cell lung cancer (NSCLC) and adopted as the second-best choice even in operable patients although local recurrence after CIRT is sometimes experienced. The purpose of this study was investigate demographic data, perioperative courses therapeutic outcomes who underwent salvage resection CIRT.From November 1994 February 2012, applied 602 c-T1/T2/T3N0M0 NSCLC lesions 599 at National Institute...
The aim of this study was to investigate the clinical value 3'-deoxy-3'-[F]fluorothymidine-positron emission tomography/computed tomography (FLT-PET/CT) for lung cancer patients receiving carbon-ion radiotherapy.Twenty consecutive with underwent FLT-PET/CT before and after radiotherapy. Fifty minutes intravenous injection approximately 300 MBq FLT, PET/CT data were acquired. Maximal standardized uptake tumor measured, from which reduction rate FLT calculated. After treatment, followed (17-42...